Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

By sjmartinez • September 1, 2024

Park H, Klempner SJ, Chao J, Wainberg ZA, Lukanowski M, Chenji S, Bourke S, Chatterjee A, Lorenzen S. Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option. Front Oncol. 2024 Aug 13;14:1419338. doi: 10.3389/fonc.2024.1419338. PMID: 39206150; PMCID: PMC11353394.

Tags: FOLFIRI, gastroesophageal adenocarcinoma, Hematology/Oncology, irinotecan, Publications, ramucirumab, second-line

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease

Prueksapraopong C, Fernandes A, Campo Fernandez B, Roy S, Hollis RP, Habtemariam B, Pellin D, Ceoldo G, Lin TY, Dang TT, Cornetta K, Romero Z,[...]

Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic Breast Cancer: A Brief Report of a Clinical Trial

Henneghan A, Wertheimer J, Kim S, Gresham G, Shirazipour CH, Jones B, Asher A. Sustained Effects of a 6-Week Resiliency Program for Women with Metastatic[...]

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia

Jang J, Nold T, Marshalek JP, Matthiesen J, Tomassetti S. Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. J Oncol[...]